United States — Food and Drug Administration & Pomerantz LLP
13 shared events · Importance 3 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.
Pomerantz LLP: Pomerantz LLP is a law firm that has filed a class action lawsuit against ImmunityBio on behalf of investors.
Apr 02, 2026 · 132 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to JK Industries for significant violations of Current Good Manufacturing Practice regulations, which triggered the investigation and stock price drop.
Pomerantz LLP: Pomerantz LLP is investigating claims on behalf of investors of JK Industries regarding potential securities fraud and unlawful business practices.
Jun 16, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs related to Zoetis' Bedinvetmab, contributing to its weakening adoption.
Pomerantz LLP: Pomerantz LLP is the law firm that filed the class action lawsuit against Zoetis, representing investors who suffered losses. This event enhances the firm's reputation in corporate and securities litigation.
May 18, 2026 · 316 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration placed a full clinical hold on MiNK Therapeutics' investigational new drug application for ARD-101, directly impacting the company's drug development and stock performance.
Pomerantz LLP: Pomerantz LLP is initiating an investigation into MiNK Therapeutics for potential securities fraud, aiming to represent investors who suffered losses. This action enhances Pomerantz LLP's business and reputation in class action litigation.
May 21, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.
Pomerantz LLP: Pomerantz LLP announces a class action lawsuit against Aldeyra Therapeutics, advising investors to contact them regarding the case.
Apr 24, 2026 · 80 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration's delayed clearance for Caris Life Sciences' TriNav Advance product is a key factor contributing to the company's financial issues and the subsequent investor investigations.
Pomerantz LLP: Pomerantz LLP is investigating claims on behalf of investors of Caris Life Sciences for potential securities fraud and other unlawful business practices.
Jun 02, 2026 · 31 articles
Regulatory
United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.
Pomerantz LLP: Pomerantz LLP is one of the law firms investigating claims and filing class actions against Replimune, representing investors. The firm may benefit from successful litigation.
Jul 29, 2026 · 65 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Oculis will not pursue a filing with for its drug candidate OCS-01, following the failed clinical trials.
Pomerantz LLP: Pomerantz LLP is investigating Oculis for potential securities fraud and unlawful business practices on behalf of investors. This firm is actively seeking investors to join a class action lawsuit.
May 29, 2026 · 43 articles
Regulatory
United States — Food and Drug Administration: The FDA approved Celcuity's therapy, but the approval was expected; the delay in launch is the issue.
Pomerantz LLP: Pomerantz LLP is conducting the investigation into Celcuity for potential securities fraud.
Jul 17, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Pomerantz LLP interact across events, view sentiment trends, and discover connected entities.
Open Dashboard